177Lu标记的抗紧密连接蛋白6单克隆抗体用于食管癌靶向治疗
研究评估紧密连接蛋白6(CLDN6)能否作为食管癌(EC)成像与放射药物治疗的靶点。在2个EC数据集(n=436)及109例EC患者回顾分析中,CLDN6信使RNA在EC中升高,EC组织表达率为79.8%而健康食管组织为0。使用[89Zr]Zr-DFO-IMAB027 PET成像可清晰显示高表达CLDN6的移植瘤,[177Lu]Lu-DOTA-IMAB027在TE-1-CLDN6与CLDN6-PDX模型中诱导快速肿瘤退缩。
要点
- CLDN6信使RNA在EC中较健康食管组织升高,EC组织表达率79.8%而健康食管组织为0。
- [89Zr]Zr-DFO-IMAB027 PET可有效成像高表达CLDN6的EC移植瘤。
- [177Lu]Lu-DOTA-IMAB027在TE-1-CLDN6与CLDN6-PDX模型中诱导快速肿瘤退缩。
核心结论
- CLDN6在肿瘤与正常食管间的差异表达显示其作为EC诊断和治疗靶点的潜力。
- [89Zr]Zr-DFO-IMAB027在显示表达CLDN6的移植瘤时对比度高,可用于PET成像。
- [177Lu]Lu-DOTA-IMAB027在TE-1-CLDN6和CLDN6-PDX两种模型中均诱导快速肿瘤退缩。
- 该研究对改进EC的放射配体诊断与治疗具有意义。
研究设计与样本
- 评估CLDN6信使RNA在2个EC数据集(n=436)中的表达。
- 回顾性分析109例EC患者。
- 使用89Zr和177Lu标记的抗CLDN6单克隆抗体IMAB027([89Zr]Zr-DFO-IMAB027与[177Lu]Lu-DOTA-IMAB027)分别进行PET成像和治疗。
- 使用TE-1-CLDN6移植瘤模型进行成像与生物分布分析。
- 在TE-1-CLDN6和CLDN6-PDX(患者来源移植瘤)模型中评估[177Lu]Lu-DOTA-IMAB027的治疗潜力。
主要发现
- CLDN6信使RNA在EC中较健康食管组织升高。
- CLDN6表达率在健康食管组织为0,在EC组织为79.8%。
- [89Zr]Zr-DFO-IMAB027能有效成像高表达CLDN6的EC移植瘤。
- 在TE-1-CLDN6模型中,11.1-MBq [177Lu]Lu-DOTA-IMAB027治疗组与对照组肿瘤体积差异显著(P < 0.001),该组肿瘤生长抑制率为101.74%。
- 在PDX模型中,所有[177Lu]Lu-DOTA-IMAB027治疗组与对照组肿瘤体积差异显著(P < 0.05);11.1-MBq组肿瘤生长抑制率为79.04%,3.7-MBq组为77.20%,高剂量与低剂量组疗效差异无统计学显著(P > 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Advanced or metastatic esophageal cancer (EC) is associated with poor prognosis, necessitating new and effective treatment methods. We assess whether claudin 6 (CLDN6) is a useful target for the imaging and radiopharmaceutical therapy of EC using a novel pair of radioactive nuclides, 89Zr and 177Lu. Methods: CLDN6 messenger RNA expression was evaluated in 2 EC datasets (n = 436) and through a retrospective analysis of 109 patients with EC. We then used an anti-CLDN6 monoclonal antibody (IMAB027) labeled with 89Zr and 177Lu ([89Zr]Zr-DFO-IMAB027 and [177Lu]Lu-DOTA-IMAB027) for PET imaging and therapy, respectively. Imaging and biodistribution analyses were performed using the TE-1-CLDN6 xenograft model. Finally, the therapeutic potential of [177Lu]Lu-DOTA-IMAB027 was evaluated in both the TE-1-CLDN6 and the CLDN6-PDX (patient-derived xenograft) models. Results: CLDN6 messenger RNA expression was elevated in EC compared with healthy esophageal tissues. The CLDN6 expression rate was 0 in healthy esophageal tissue but was 79.8% in EC tissue. The [89Zr]Zr-DFO-IMAB027 showed the ability to effectively image EC xenografts with high CLDN6 expression. In the TE-1-CLDN6 model, there was a significant difference in tumor volume between the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 treatment group and the control group (P < 0.001). The tumor growth inhibition rate in the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 group was 101.74%. In the PDX model, significant differences in tumor volume were observed among all [177Lu]Lu-DOTA-IMAB027 treatment groups and the control group (P < 0.05). Specifically, the tumor growth inhibition rate of the 11.1-MBq [177Lu]Lu-DOTA-IMAB027 group was 79.04%, whereas that of the 3.7-MBq group was 77.20%. However, the difference in efficacy between the high-dose and low-dose groups was not statistically significant (P > 0.05). Conclusion: The differential expression of CLDN6 between tumors and the normal esophagus shows its potential as a diagnostic and therapeutic target for EC. The radiotracer [89Zr]Zr-DFO-IMAB027 showed high contrast when visualizing CLDN6-expressing xenografts for PET imaging, and [177Lu]Lu-DOTA-IMAB027 induced rapid tumor regression in both the TE-1-CLDN6 and the CLDN6-PDX models. This research has implications for improving the radioligand diagnosis and treatment of EC.
引用
- Du H, Hao X, Lin B, et al. 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer. J Nucl Med. 2025. PMID: 39915118. doi:10.2967/jnumed.124.268487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。